Enver Akalin, MD
Nephrology · Bronx, NYNPI 1407885205
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $85,017 of the $100,954 with a category attached, or 84.2%. 14 manufacturers reported payments, led by Immucor, Inc. at 49.0% of the total. Among nephrology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 56 payments — averaging $1802.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Immucor, Inc.$50K
- Takeda Pharmaceuticals U.S.A., Inc.$27K
- Otsuka America Pharmaceutical, Inc.$9K
- Apellis Pharmaceuticals, Inc.$5K
- Mallinckrodt Enterprises LLC$4K
- Gilead$3K
- plus $3K from 8 others
Across 45 payments — averaging $4680.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Mallinckrodt Hospital Products Inc.$177K
- Astellas Pharma Global Development$20K
- CSL Behring$14K
What the payments were for
- Consulting fees$85,01784%
- Travel & lodging$14,48914%
- Food & beverage$1,4481%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Immucor, Inc. | 3 | $49,500 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $27,006 |
| Otsuka America Pharmaceutical, Inc. | 9 | $8,945 |
| Apellis Pharmaceuticals, Inc. | 1 | $4,602 |
| Mallinckrodt Enterprises LLC | 2 | $4,262 |
| Gilead | 7 | $3,202 |
| Calliditas Therapeutics US Inc. | 2 | $2,528 |
| AbbVie | 10 | $337 |
| Novartis | 3 | $290 |
| Sanofi-aventis U.S. LLC | 1 | $97 |
| Veloxis Pharmaceuticals, Inc. | 2 | $59 |
| Kamada Ltd. | 1 | $48 |
| Sanofi | 2 | $41 |
| Johnson & Johnson | 2 | $39 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GAMMAGARD LIQUID$22,831
- ACTHAR$4,262
- Vemlidy$3,000
- TARPEYO$2,500
How this compares
$100,954 in reported general payments places this provider in the 95th percentile of 935 nephrology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 87 | $75,358 |
| Cinacalcet Hcl | 36 | $29,862 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 11 | $21,514 |
| Tacrolimus | 112 | $20,318 |
| FarxigaDapagliflozin Propanediol | 18 | $16,540 |
| Atovaquone | 20 | $12,654 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $10,549 |
| Nifedipine ErNifedipine | 323 | $8,455 |
| TradjentaLinagliptin | 15 | $7,451 |
| Mycophenolate Mofetil | 71 | $7,284 |
| Novolog FlexpenInsulin Aspart | 20 | $5,235 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 19 | $5,032 |
| Valganciclovir Hcl | 22 | $4,686 |
| Semglee (Yfgn) PenInsulin Glargine-Yfgn | 14 | $2,478 |
| Atorvastatin Calcium | 275 | $2,332 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Bronx
- Bruce SpinowitzBronx$465K
- Joel NeugartenBronx$248K
- John KangBronx$93K
- Daniel AddankiBronx$54K
- Chaim CharytanBronx$34K
- Payam ShakouriPoughkeepsie$930K
- Gerald AppelNew York$842K
- Richard ChanNew York$514K
- Steven CocaNew York$445K
- Joseph RoglieriTroy$425K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.